Compare ASMB & HCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | HCKT |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 392.0M |
| IPO Year | 2010 | 1998 |
| Metric | ASMB | HCKT |
|---|---|---|
| Price | $28.40 | $14.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.40 | $17.00 |
| AVG Volume (30 Days) | 93.3K | ★ 320.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.38% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | N/A | ★ $285,862,000.00 |
| Revenue This Year | $33.33 | $2.55 |
| Revenue Next Year | N/A | $5.07 |
| P/E Ratio | ★ N/A | $30.87 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.76 | $12.76 |
| 52 Week High | $39.71 | $29.52 |
| Indicator | ASMB | HCKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 40.25 |
| Support Level | $26.50 | $12.76 |
| Resistance Level | $31.11 | $21.13 |
| Average True Range (ATR) | 1.84 | 0.64 |
| MACD | 0.11 | 0.23 |
| Stochastic Oscillator | 57.55 | 57.03 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.